Biotron Ltd (ASX: BIT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Biotron Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $64.58 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 701.93 million
Earnings per share -0.006
Dividend per share N/A
Year To Date Return 28.21%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Biotron Ltd (ASX: BIT)
Latest News

BIT ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Biotron Ltd

Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.

BIT Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
30 Nov 2021 $0.09 $-0.01 -10.00% 15,650,943 $0.10 $0.11 $0.09
29 Nov 2021 $0.10 $0.01 11.63% 29,830,913 $0.10 $0.11 $0.10
26 Nov 2021 $0.09 $-0.01 -10.00% 45,753,466 $0.11 $0.12 $0.08
25 Nov 2021 $0.10 $0.05 98.04% 161,351,267 $0.07 $0.11 $0.07
24 Nov 2021 $0.05 $0.00 0.00% 110,694 $0.05 $0.05 $0.05
23 Nov 2021 $0.05 $0.00 0.00% 1,508,616 $0.05 $0.05 $0.05
22 Nov 2021 $0.05 $0.00 0.00% 1,196,508 $0.05 $0.05 $0.05
19 Nov 2021 $0.05 $0.00 0.00% 453,555 $0.05 $0.05 $0.05
18 Nov 2021 $0.05 $0.00 0.00% 366,294 $0.05 $0.05 $0.05
17 Nov 2021 $0.05 $0.00 0.00% 359,454 $0.05 $0.05 $0.05
16 Nov 2021 $0.05 $0.00 0.00% 126,478 $0.05 $0.05 $0.05
15 Nov 2021 $0.05 $0.00 0.00% 1,642,585 $0.05 $0.05 $0.05
12 Nov 2021 $0.05 $0.00 0.00% 480,261 $0.05 $0.05 $0.05
11 Nov 2021 $0.05 $0.00 0.00% 628,628 $0.05 $0.05 $0.05
10 Nov 2021 $0.05 $0.00 0.00% 431,830 $0.05 $0.05 $0.05
09 Nov 2021 $0.05 $0.00 0.00% 314,405 $0.05 $0.05 $0.05
08 Nov 2021 $0.05 $0.00 0.00% 810,003 $0.05 $0.05 $0.05
05 Nov 2021 $0.05 $0.00 0.00% 486,842 $0.05 $0.05 $0.05
04 Nov 2021 $0.05 $0.00 0.00% 607,890 $0.05 $0.05 $0.05
03 Nov 2021 $0.05 $0.00 0.00% 437,360 $0.05 $0.05 $0.05
02 Nov 2021 $0.05 $0.00 0.00% 1,408,556 $0.05 $0.05 $0.05

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Michael J Hoy Non-Executive DirectorNon-Executive Chairman Feb 2000
Mr Hoy has more than 30 years of corporate experience in Australia, the United Kingdom, USA and Asia. He is Chairman of Lipotek Pty Limited and a former director of John Fairfax Holdings Limited and FXF Trust.
Mr Robert Bain Thomas Non-Executive Director Mar 2012
Mr Thomas has over 35 years of experience in the securities industry, with Potter Partners (now UBS), County NatWest and Citigroup. He is the chairman of Starpharma Holdings Limited and a director of Clarity Pharmaceuticals Limited. He chairs Grahger Retail Securities Pty Ltd and is a director of O'Connell Street Associates Pty Limited.
Dr Michelle Miller Managing Director Jun 2002
Dr Miller has worked for over 25 years in the bioscience industry, with experience in commercial drug development. Her experience includes several years at Johnson & Johnson developing antiHIV gene therapeutics through preclinical research to clinical trials. She has finance industry experience from time spent as an Investment Manager with a bioscience venture capital fund.
Dr Susan Margaret Pond Non-Executive Director Mar 2012
Dr Pond has a scientific and commercial background having held executive positions in the biotechnology and pharmaceutical industry for 12 years, most recently as chairman and managing director of Johnson & Johnson Research Pty Limited (2003 - 2009). Previous non-executive positions include chair of AusBiotech Limited and director of Australian Nuclear Science and Technology Organisation, Wound Management Innovation CRC and Australian Academy of Technological Sciences and Engineering (ATSE). Dr Pond also served as a board member of Commercialisation Australia and Innovation Australia. Dr Pond is currently chair of the New South Wales Smart Sensing Network, director of the Trusted Autonomous Systems Defence Cooperative Research Centre, Vectus Biosystems Ltd, Cannatrek Ltd and the Australian Phenomics Network and Governor in Council of the Queensland University of Technology.
Professor Stephen Alister Locarnini Non-Executive Director Oct 2018
Prof Locarnini is a past director of the World Health Organisation (WHO) Regional Reference Laboratory for Hepatitis B and D for the Western Pacific Region (WPRO). He is a named inventor on over 20 internationally granted patents. He worked at the Victorian Infectious Diseases Reference Laboratory (VIDRL, originally Fairfield Hospital Virus Laboratory) from 1989, as Director of Laboratory Services from 1990 to 1998 and, in 1993, he oversaw the amalgamation of all the Fairfield Laboratories into the one service of the VIDRL. He subsequently assumed the position of Head, Research & Molecular Development of VIDRL when the laboratory relocated to Melbourne Health in 1998. Professor Locarnini currently has an academic appointment at the University of Melbourne. He is a member of the Scientific Advisory Board of a number of emerging as well as established pharmaceutical and biotechnology companies. In 2017, he co-founded the biotech start-up company CLEAR-B with the Morningside-Newton Investment group in Boston, USA focusing on curative strategies for chronic hepatitis B.
Mr Peter James Nightingale Company Secretary Feb 1999
-
Peter James Nightingale Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Jey Investment Pty Ltd 14,440,945 2.06%
Dr Angela Fay Dulhunty 10,000,000 1.42%
Umbiram Pty Ltd <Michael Hoy Super Fund A/C> 9,347,793 1.33%
Citicorp Nominees Pty Limited 8,427,055 1.20%
Jimmy Thomas and Ivy Ruth Ponniah 8,372,057 1.19%
DNS Accounting and Law Consultancy Pty Ltd 8,254,558 1.18%
Armco Barriers Pty Ltd 7,000,000 1.00%
Fordholm Investments Pty Ltd <Fordholm Super Fund A/C> 7,000,000 1.00%
Rookharp Capital Pty Limited 7,000,000 1.00%
Pathold No 222 Pty Ltd 5,250,000 0.75%
Scott s A V Pty Ltd <Scotts Acorn EMP S/F A/C> 4,918,000 0.70%
Edstop Pty Limited <Superannuation Fund A/C> 4,571,588 0.65%
William John Dunn 4,400,000 0.63%
Attollo Copia Pty Ltd <F A Pires Super Fund A/C> 4,300,565 0.61%
Travis Paul Gloury 3,779,784 0.54%
Robert Thomas and Kyrenia Thomas <Rob Thomas Super Fund A/C> 3,663,195 0.52%
Dr Sanjiv Pathak 3,632,313 0.52%
Peter James Nightingale 3,594,903 0.51%
Alpha Matilda Trading Pty Ltd <Alpha Matilda Superfund A/C> 3,337,472 0.48%
Mark Andrew Peterson 3,332,000 0.47%

Profile

since

Note